Verition Fund Management
IBRX icon

Verition Fund Management’s ImmunityBio IBRX Stock Holding History

Verition Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-77,118
Closed -$528K – 2880
2025
Q4 		$153K Sell
77,118
-141,063
-65% -$320K ﹤0.01% 3243
2025
Q3 		$537K Sell
218,181
-27,620
-11% -$71.1K ﹤0.01% 2983
2025
Q2 		$649K Sell
245,801
-581,238
-70% -$1.56M ﹤0.01% 2773
2025
Q1 		$2.49M Buy
827,039
+776,709
+1,543% +$2.35M 0.01% 1419
2024
Q4 		$129K Sell
50,330
-43,940
-47% -$183K ﹤0.01% 3053
2024
Q3 		$351K Buy
94,270
+53,607
+132% +$248K ﹤0.01% 2545
2024
Q2 		$257K Buy
+40,663
New +$268K ﹤0.01% 2440
2023
Q4 		– Sell
-84,770
Closed -$143K – 2494
2023
Q3 		$143K Buy
+84,770
New +$170K ﹤0.01% 2062
2023
Q2 		– Sell
-13,625
Closed -$24.8K – 2360
2023
Q1 		$24.8K Buy
+13,625
New +$42.4K ﹤0.01% 1998

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Verition Fund Management's IBRX Position: Q1 2026 in Review

Verition Fund Management sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 77,118 shares — an estimated $528K sold.

Verition Fund Management first reported a position in IBRX in Q1 2023 and held it in 9 quarters. The position peaked at $2.49M in Q1 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Verition Fund Management reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 77,118 ImmunityBio shares in Q1 2026, an estimated $528K.
  • Verition Fund Management first reported a position in ImmunityBio in Q1 2023 and held it in 9 quarters.
  • Verition Fund Management's ImmunityBio position peaked at $2.49M in Q1 2025.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.